G E Grau, D N Maennel. Show Affiliations »
Abstract
Entities: Gene
Mesh: See more » AnimalsAntigens, CD/administration & dosageAntigens, CD/therapeutic useClinical Trials as TopicDrug Administration ScheduleHumansImmunoglobulin Heavy Chains/administration & dosageImmunoglobulin Heavy Chains/therapeutic useImmunoglobulin gamma-ChainsMiceMice, KnockoutPapioReceptors, Tumor Necrosis Factor/administration & dosageReceptors, Tumor Necrosis Factor/therapeutic useReceptors, Tumor Necrosis Factor, Type IIRecombinant Fusion Proteins/administration & dosageRecombinant Fusion Proteins/therapeutic useSepsis/drug therapySepsis/immunologySepsis/mortalityTumor Necrosis Factor-alpha/antagonists & inhibitors
Substances: See more » Antigens, CDImmunoglobulin Heavy ChainsImmunoglobulin gamma-ChainsReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type IIRecombinant Fusion ProteinsTumor Necrosis Factor-alphaRo 45-2081
Year: 1997 PMID: 9359687 DOI: 10.1038/nm1197-1193
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440